May 9th 2024
During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that looked at outcomes of dose optimization of regorafenib for patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Ensituximab Proves Promising in Refractory mCRC
April 14th 2016Treatment with ensituximab (NPC-1C), a chimeric IgG1 monoclonal antibody, induced stable disease in nearly half of patients with chemotherapy-refractory metastatic colorectal cancer (mCRC) without contributing significant toxicity.
Read More
Liver-Directed Therapy Shows Promise in Select Patients With mCRC
March 14th 2016The addition of Yttrium-90 (Y-90) resin microspheres (SIR-Spheres) to standard frontline FOLFOX-based chemotherapy with or without bevacizumab significantly improved liver-specific progression-free survival (PFS) for patients with liver metastatic colorectal cancer (CRC), according to findings from the phase III SIRFLOX study published in the Journal of Clinical Oncology.
Read More
Ziv-Aflibercept Plus Capecitabine Combo Active, Well-Tolerated in mCRC
March 2nd 2016The combination of ziv-aflibercept and capecitabine demonstrated an acceptable safety profile and encouraging clinical efficacy for patients with metastatic colorectal cancer, according to findings from the ongoing phase II X-TRAP trial.
Read More
Two Options Allows for Treatment Tailoring in Refractory CRC
February 18th 2016Treatments can be better customized and tailored based on each patient's individual desires and characteristics, now that two effective options are available for refractory metastatic colorectal cancer, according to Jennifer Wu, MD.
Read More
Dr. Jennifer Wu on Proliferations and Mutations in Colorectal Cancer
February 12th 2016Jennifer Wu, MD, discusses the issue of deficiencies in enzymes that fix mismatch repairs in colorectal cancer. Wu says targeting the cancer-specific enzymes which allow tumors to repair themselves could stop tumor growth in patients.
Watch